PBAC's latest decision on Hypromellose: Recommended (2021). Considered for Treatment of severe dry eye syndrome, including Sjogren's syndrome. The product provides temporary relief of symptoms due to dry eye (e.g. burning, irritation and discomfort) and is suitable for use with contact lenses.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2018
Submissions
2
2018 → 2021
Eligible population
Adults with severe dry eye syndrome, including Sjogren's syndrome, receiving treatment under a GP Management Plan or Team Care Arrangements.
Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Genteal and In a Wink Moisturising (existing PBS-listed hypromellose brands)
Economic model
Cost-minimisation
Eligible patients/year
80,000
ICER note
Cost-minimisation submission; no ICER calculated. This is a generic brand listing with estimated net cost saving to PBS/RPBS over six years.
Submission history
Nov 2018: Recommended with restriction · Restricted